← 產業報告目錄

Proteins & Protein Crystals Market by Product Type (Enzyme, Monoclonal Antibodies, Insulin, Hormones); Structural (Membrane, Matrix), Specialty (Nutrition, Analytics, Cosmetics); Application (Healthcare, Environmental); End User (Pharma, Biotech, CROs) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Machinery & Equipment出版日期 2026-01-28頁數 303報告編號 AST10005

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global protein and protein crystals market is projected to reach USD 960.37 billion by 2030 from USD 609.51 billion in 2025, at a CAGR of 9.5% from 2025 to 2030. The protein and protein crystals market is primarily driven by the growing demand for biopharmaceuticals, increasing R&D in structural biology and drug discovery, and the rising use of proteins in diagnostics, therapeutics, and industrial applications. Enzymatic proteins lead the market due to their wide use in therapeutics, industrial biocatalysis, and high-throughput screening, while recombinant and monoclonal proteins drive demand in drug development and personalized medicine because of their specificity and scalability. Additionally, the growing adoption of protein crystallization kits, reagents, and automated crystallization platforms for structural studies further fuels the market, as researchers and pharmaceutical companies increasingly rely on these products to determine protein structures, accelerate drug design, and enhance enzyme-based industrial processes. By product type, the structural proteins segment is expected to register the highest CAGR during the forecast period. By product type, the structural proteins segment is expected to account for the highest CAGR in the protein and protein crystals market. The growth of the structural proteins segment in the protein and protein crystals market is driven by multiple factors across research, healthcare, and industrial applications. Research proteins such as actin and tubulin are in high demand for structural biology, high-throughput crystallography, and drug discovery, enabling precise protein structure determination and rational drug design. Membrane proteins are increasingly sought after as critical therapeutic targets in the development of biologics and precision medicine. Connective tissue and extracellular matrix proteins, including collagen, elastin, laminins, and proteoglycans, are fueling demand in biomaterials, tissue engineering, and regenerative medicine, as well as in cosmetic and healthcare products. By application, the healthcare segment accounted for the highest CAGR of the market in 2024. The healthcare application segment is expected to register the highest CAGR in the proteins and protein crystals market due to the increasing demand for therapeutic proteins, monoclonal antibodies, vaccines, and diagnostic enzymes. Growing prevalence of chronic diseases, cancer, and metabolic disorders is driving the development and use of protein-based biologics, while advances in structural biology and protein crystallography are accelerating drug discovery and targeted therapy. Rising investments in biopharmaceutical R&D, clinical research, and high-throughput protein analysis are fueling the adoption of protein crystals and related products in healthcare, making this segment the fastest-growing compared with industrial, food, and research applications. as therapeutic and structural proteins are increasingly being used in biologics development. The rising incidence of hereditary and chronic diseases is driving the need for protein-based treatments. Precise structure-based drug design is made possible by developments in protein crystallography, which drives biopharmaceutical innovation. Expanding clinical applications and higher R&D expenditures also contribute to this market's growth. Asia Pacific is expected to register the highest growth rate in the market during the forecast period. The Asia-Pacific region is expected to register the highest CAGR in the protein and protein crystals market due to strong growth across healthcare, research, and other applications. In healthcare, increasing biopharmaceutical R&D, rising prevalence of chronic diseases, and adoption of personalized medicine are driving demand for therapeutic proteins, monoclonal antibodies, and protein-based diagnostics. In research and academia, expanding life sciences infrastructure, CROs, and structural biology initiatives boost the use of protein crystallization kits and reagents. Other applications are contributing to market growth, in agriculture and animal health, proteins and enzymes are used for feed additives, vaccines, and disease management; in cosmetics, structural proteins like collagen and elastin are applied in anti-aging and skincare products; and in bioenergy, enzymes facilitate biomass conversion and biofuel production. The combined demand across healthcare, research, agriculture, animal health, cosmetics, and bioenergy is fueling rapid market growth in Asia-Pacific. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (55%), Directors (27%), and Others (18%) By Region: North America (35%), Europe (32%), Asia Pacific (25%), Latin America (6%), and the Middle East & Africa (2%) The prominent players in this market are Danaher (US), Thermo Fischer Scientific inc. (US), Sanofi (France), Agilent (US), Takeda Pharmaceutical Company (Japan), International Flavours and Fragrances (US), Biocon (India), RayBiotech (US), Merck KGaA (Germany), Amgen (US), Eli lilly (US), Roche (Switzerland), Novo Nordisk (Denmark), and Pfizer (US), among others. Research Coverage The protein and protein crystals market is segmented by product type, application, end user, and region. Key factors influencing market growth include driving forces, restraints, opportunities, and challenges for stakeholders. The report also reviews the leading companies competing in the Protein and Pprotein Ccrystals market. A micro-level analysis can be conducted to examine trends, growth opportunities, and contributions to the market. Additionally, it highlights potential revenue growth opportunities across various market segments in five major regions. Key Benefits of Buying the Report The report is valuable for new entrants in the protein and protein crystals market as it provides comprehensive information about the market. This information is essential for understanding various investment opportunities. The report provides insights into both key and smaller players in the market, which can help create a solid basis for risk analysis when making investment decisions. It accurately segments the market by end users and regions, providing focused insights into specific market segments. Additionally, the report highlights key trends, challenges, growth drivers, and opportunities to support strategic decision-making through a thorough analysis. The report provides insights into the following points: • Key drivers (Rising demand for therapeutic proteins, Advancements in protein crystallization and structural biology, increasing applications in food processing and industrial biotechnology), restraints (High production and purification costs, Limited stability and storage of protein-based products), opportunities (Emergence of AI and automation in protein crystallography, Integration of hybrid and 3D printing technologies, Collaborations between academia and industry), and challenges (reproducibility issues in protein crystallization, Competition from alternative analytical techniques) • Product Development/Innovation: Emerging technologies in space, R&D, recent product launches & approvals in the protein and protein crystals market. • Market Growth: In-depth insights into remunerative markets report analyze the protein and protein crystals market across varied geographies. • Market Diversification: Detailed analysis of new products, unexplored geographies, latest trends, and investments in the protein and protein crystals market • Competitive Assessment: Detailed assessment of market share, service offerings, leading strategies of major players such as Danaher (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La F. Hoffmann-La Roche AG (Switzerland), Roche Ltd (Germany), Amgen (US) and Merck KGaA (Germany), among others..
目錄 Table of Contents
1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 29 1.3 STUDY SCOPE 30 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 30 1.3.2 INCLUSIONS & EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 31 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 32 2 EXECUTIVE SUMMARY 33 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 33 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 34 2.3 DISRUPTIVE TRENDS IN PROTEINS & PROTEIN CRYSTALS MARKET 35 2.4 HIGH-GROWTH SEGMENTS 36 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 37 3 PREMIUM INSIGHTS 38 3.1 PROTEINS & PROTEIN CRYSTALS MARKET OVERVIEW 38 3.2 VALUE CHAIN ANALYSIS OF PROTEINS & PROTEIN CRYSTALS MARKET 39 3.3 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION AND END USER, 2025 40 3.4 GEOGRAPHIC SNAPSHOT OF PROTEINS & PROTEIN CRYSTALS MARKET 41 4 MARKET OVERVIEW 42 4.1 INTRODUCTION 42 4.2 MARKET DYNAMICS 42 4.2.1 DRIVERS 43 4.2.1.1 Increasing emphasis on structure‑based drug discovery and development 43 4.2.1.2 Rising demand for protein-based drug development 43 4.2.1.3 Increasing demand for therapeutic proteins 44 4.2.1.4 Technological advancements in crystallization methods 44 4.2.2 RESTRAINTS 45 4.2.2.1 High technical complexity and low success rates in protein crystallization 45 4.2.2.2 Exposure to ionizing radiation and contrast-related concerns among vulnerable populations 46 4.2.2.3 Need for high costs, technical expertise, and advanced infrastructure for commercialization 46 4.2.3 OPPORTUNITIES 47 4.2.3.1 Integration of AI-enabled innovations 47 4.2.3.2 Collaboration between academia and industry 47 4.2.3.3 High investment and funding in structural biology, biopharmaceuticals, and advanced drug development 48 4.2.4 CHALLENGES 49 4.2.4.1 Reproducibility issues in protein crystallization 49 4.2.4.2 Scalability concerns in recombinant protein production 49 4.3 UNMET NEEDS 50 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50 4.5 STRATEGIC MOVES BY TIER1/2/3 PLAYERS 50 5 INDUSTRY TRENDS 51 5.1 PORTER’S FIVE FORCES ANALYSIS 51 5.1.1 BARGAINING POWER OF BUYERS 52 5.1.2 BARGAINING POWER OF SUPPLIERS 52 5.1.3 THREAT OF NEW ENTRANTS 52 5.1.4 THREAT OF SUBSTITUTES 52 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 52 5.2 MACROECONOMIC OUTLOOK 53 5.2.1 GDP TRENDS & FORECAST 53 5.2.2 TRENDS IN GLOBAL ENVIRONMENTAL INDUSTRY 53 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 54 5.3 SUPPLY CHAIN ANALYSIS 54 5.3.1 PROMINENT COMPANIES 54 5.3.2 SMALL & MEDIUM-SIZED ENTERPRISES 54 5.3.3 END USERS 55 5.4 VALUE CHAIN ANALYSIS 55 5.4.1 RESEARCH & DEVELOPMENT 55 5.4.2 MANUFACTURING 55 5.4.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 55 5.5 ECOSYSTEM ANALYSIS 56 5.6 PRICING ANALYSIS 57 5.6.1 AVERAGE SELLING PRICE OF PROTEINS & PROTEIN CRYSTALS, BY PRODUCT, 2024 58 5.6.2 AVERAGE SELLING PRICE TREND OF PROTEINS & PROTEIN CRYSTALS, BY REGION, 2022–2024 58 5.7 TRADE ANALYSIS 60 5.7.1 IMPORT DATA FOR HS CODE 3507, 2021–2024 61 5.7.2 EXPORT DATA FOR HS CODE 3507, 2021–2024 62 5.7.3 TRADE ANALYSIS FOR HS CODE 293719 63 5.8 KEY CONFERENCES & EVENTS, 2025–2026 65 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 66 5.10 INVESTMENT & FUNDING SCENARIO 66 5.11 CASE STUDY ANALYSIS 68 5.11.1 COMPUTATIONAL DESIGN OF HIGH-AFFINITY MINIBINDER PROTEINS FOR THERAPEUTIC TARGETS 68 5.12 IMPACT OF 2025 US TARIFF ON PROTEINS & PROTEIN CRYSTALS MARKET 68 5.12.1 KEY TARIFF RATES 69 5.12.2 KEY TARIFF RATES 69 5.12.3 PRICE IMPACT ANALYSIS 69 5.12.4 IMPACT ON COUNTRY/REGION 70 5.12.4.1 North America 70 5.12.4.1.1 US 70 5.12.4.2 Europe 70 5.12.4.3 Asia Pacific 70 5.12.5 IMPACT ON END-USE INDUSTRIES 70 6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS 71 6.1 KEY EMERGING TECHNOLOGIES 71 6.1.1 CRYO-CRYSTALLIZATION 71 6.1.2 X-RAY FREE-ELECTRON LASERS (XFELS) 71 6.1.3 COMPUTATIONAL PROTEIN DESIGN TOOLS 71 6.2 COMPLEMENTARY TECHNOLOGIES 71 6.2.1 MICROFLUIDICS AND LAB-ON-A-CHIP (LOC) TECHNOLOGIES 71 6.2.2 NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY 72 6.3 PATENT ANALYSIS 72 6.4 IMPACT OF AI/GEN AI ON PROTEINS & PROTEIN CRYSTALS MARKET 73 6.4.1 TOP USE CASES AND MARKET POTENTIAL 73 6.4.2 BEST PRACTICES IN PROTEINS & PROTEIN CRYSTALS MARKET 73 6.4.3 CASE STUDIES 73 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 74 6.4.5 CLIENT’S READINESS TO ADOPT GEN AI IN PROTEINS & PROTEIN CRYSTALS MARKET 75 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 75 6.6 REGULATORY LANDSCAPE 76 6.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 6.7 INDUSTRY STANDARDS 81 6.8 CERTIFICATIONS, LABELLING, AND ECO-STANDARDS 81 6.8.1 CERTIFICATIONS & GOOD MANUFACTURING/QUALITY STANDARDS 81 6.8.2 LABELLING & TRACEABILITY 82 6.8.3 ECO-STANDARDS/ENVIRONMENTAL/SUSTAINABILITY CERTIFICATION 82   6.9 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 82 6.9.1 DECISION-MAKING PROCESS 82 6.10 KEY STAKEHOLDERS & BUYING CRITERIA 82 6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 82 6.10.2 KEY BUYING CRITERIA 83 6.11 ADOPTION BARRIERS AND INTERNAL CHALLENGES 85 6.12 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 85 7 PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE 86 7.1 INTRODUCTION 87 7.2 ENZYMATIC PROTEINS 87 7.2.1 INDUSTRIAL ENZYMES 88 7.2.1.1 Focus on green manufacturing and sustainable solutions to aid adoption 88 7.2.2 FOOD ENZYMES 89 7.2.2.1 Expansion of food-based technologies to propel market growth 89 7.3 THERAPEUTIC PROTEINS 90 7.3.1 MONOCLONAL ANTIBODIES 92 7.3.1.1 Advancing disease targeting and treatment through monoclonal antibody technologies to spur adoption 92 7.3.2 INSULIN 93 7.3.2.1 Strengthening investment scenario for insulin development to fuel market growth 93 7.3.3 HORMONES 94 7.3.3.1 Introduction of new drugs and therapies for hormonal diseases to propel segment growth 94 7.3.4 COAGULATION FACTORS 95 7.3.4.1 Enhanced hemostasis therapies through advanced coagulation protein technologies to augment market growth 95 7.4 STRUCTURAL PROTEINS 96 7.4.1 RESEARCH PROTEINS 97 7.4.1.1 Research proteins to empower drug discovery and molecular research with AI integration 97 7.4.2 STRUCTURAL PROTEINS 98 7.4.2.1 Advancements in structural protein through collagen and connective tissue insights to fuel market growth 98 7.5 SPECIALTY PROTEINS 99 7.5.1 INDUSTRIAL PROTEINS 100 7.5.1.1 Industrial proteins to optimize industrial processes through advanced protein technologies 100 7.5.2 NUTRITIONAL PROTEINS 101 7.5.2.1 Nutritional proteins to enable evidence-based, disease-specific nutrition for complementing pharmaceutical therapies 101 7.5.3 ANALYTICAL PROTEINS 102 7.5.3.1 Analytical proteins to support quality control and scientific discovery 102 7.5.4 COSMECEUTICAL PROTEINS 102 7.5.4.1 Focus on innovative personal care products to support segment growth 102 7.5.5 FUNTIONAL FOOD PROTEINS 103 7.5.5.1 Functional foods & beverages with advanced proteins to improve digestibility of nutritional profile 103 8 PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION 105 8.1 INTRODUCTION 106 8.2 HEALTHCARE 107 8.2.1 ADVANCEMENTS IN PROTEIN ENGINEERING, STRUCTURAL BIOLOGY, AND HIGH-THROUGHPUT CRYSTALLIZATION TO SPUR MARKET 107 8.3 TISSUE ENGINEERING 108 8.3.1 DEVELOPMENT OF ADVANCED REGENERATIVE MEDICINE THROUGH PROTEIN-BASED TISSUE ENGINEERING TO AID MARKET GROWTH 108 8.4 AGRICULTURE & ANIMAL NUTRITION 109 8.4.1 FOCUS ON BETTER AGRICULTURAL PRODUCTIVITY AND ANIMAL HEALTH THROUGH PROTEIN-BASED SOLUTIONS TO DRIVE MARKET 109 8.5 INDUSTRIAL PROCESSING 110 8.5.1 GROWING DEMAND FOR HIGH-PERFORMANCE AND ECO-FRIENDLY PRODUCTS TO DRIVE MARKET GROWTH 110 8.6 BIOENERGY & ENVIRONMENTAL 111 8.6.1 GROWING DEMAND FOR SUSTAINABLE ENERGY AND ECO-FRIENDLY SOLUTIONS TO BOOST MARKET GROWTH 111 8.7 COMECEUTICALS & NUTRACEUTICALS 112 8.7.1 ADVANCEMENTS IN PROTEIN-BASED NUTRACEUTICALS TO ENHANCE DIGESTIBILITY AND NUTRIENT DELIVERY 112 8.8 OTHER APPLICATIONS 113 9 PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER 114 9.1 INTRODUCTION 115 9.2 PHARMA INDUSTRY 115 9.2.1 DRUG DEVELOPMENT 116 9.2.1.1 Increased internal biologics discovery and process-development activity to augment market growth 116 9.2.2 FORMULATION/MANUFACTURING 117 9.2.2.1 Advancing protein therapeutics through optimized formulation and manufacturing to propel segment growth 117 9.2.3 STORAGE/INVENTORY MANAGEMENT 118 9.2.3.1 Optimal storage/inventory management to optimize supply, reduce waste, and prevent stockouts 118 9.3 BIOTECHNOLOGY INDUSTRY 119 9.3.1 DRUG DEVELOPMENT 120 9.3.1.1 Growth of precision/personalized medicines and advanced therapeutics to aid segment growth 120   9.3.2 FORMULATION/MANUFACTURING 121 9.3.2.1 Expansion of manufacturing facilities in biotechnology industry leading to support market growth 121 9.3.3 STORAGE/INVENTORY MANAGEMENT 122 9.3.3.1 Optimizing storage and inventory management for proteins and protein crystals to enhance safety, quality, and accessibility 122 9.4 RESEARCH, ACADEMIA, AND CROS 123 9.4.1 DRUG DEVELOPMENT & DISCOVERY 124 9.4.1.1 Focus on accelerating advancements protein & protein crystal applications to fuel segment growth 124 9.4.2 LIFE SCIENCE RESEARCH 125 9.4.2.1 Expanding scope of research for formulating targeted treatment strategies to boost Market 125 9.5 FOOD & BEVERAGE INDUSTRY 126 9.5.1 INCREASING DEMAND FOR HIGH PROTEIN DIETS, NUTRITIONAL SUPPLEMENTS, AND FUNCTIONAL FOODS TO AID MARKET GROWTH 126 9.6 OTHER END USERS 127 10 PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION 128 10.1 INTRODUCTION 129 10.2 NORTH AMERICA 129 10.2.1 US 133 10.2.1.1 US to dominate North American proteins & protein crystals market during study period 133 10.2.2 CANADA 136 10.2.2.1 Innovations in protein AI to drive advanced protein design and structure prediction 136 10.3 EUROPE 138 10.3.1 GERMANY 141 10.3.1.1 Favorable healthcare policies and regulatory landscape to drive market 141 10.3.2 UK 144 10.3.2.1 Favorable regulatory scenario for protein & protein crystal development to support market growth 144 10.3.3 FRANCE 146 10.3.3.1 Increased healthcare funding by government bodies to aid market growth 146 10.3.4 ITALY 149 10.3.4.1 Increased availability of reimbursement coverage for proteins and protein crystals to augment market growth 149 10.3.5 SPAIN 151 10.3.5.1 Ongoing research linking crystallography to disease mechanisms and infrastructure development to aid market growth 151 10.3.6 REST OF EUROPE 153   10.4 ASIA PACIFIC 155 10.4.1 CHINA 159 10.4.1.1 Emphasis on modernization and expansion of healthcare infrastructure to drive market 159 10.4.2 JAPAN 162 10.4.2.1 Rise in research applications using proteins & protein crystals to propel market growth 162 10.4.3 INDIA 164 10.4.3.1 Investments and funding activities in Indian biotechnology and biopharma industry to augment market growth 164 10.4.4 AUSTRALIA 167 10.4.4.1 Rising investments in healthcare infrastructure to drive market 167 10.4.5 SOUTH KOREA 169 10.4.5.1 Strong academic & research infrastructure and favorable national funding programs to aid market growth 169 10.4.6 REST OF ASIA PACIFIC 171 10.5 LATIN AMERICA 173 10.5.1 BRAZIL 177 10.5.1.1 Growing adoption of proteins in research centers and workshops to propel market growth 177 10.5.2 MEXICO 179 10.5.2.1 Increasing investments and funding for development and manufacturing of protein-based APIs to drive market 179 10.5.3 REST OF LATIN AMERICA 182 10.6 MIDDLE EAST & AFRICA 184 10.6.1 GCC COUNTRIES 187 10.6.1.1 Government initiatives for better digital health and improved telemedicine to drive market 187 10.6.2 REST OF MIDDLE EAST & AFRICA 190 11 COMPETITIVE LANDSCAPE 192 11.1 INTRODUCTION 192 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 192 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET 192 11.3 REVENUE ANALYSIS, 2021–2024 194 11.4 MARKET SHARE ANALYSIS, 2024 195 11.5 COMPANY VALUATION & FINANCIAL METRICS 197 11.5.1 FINANCIAL METRICS 197 11.5.2 COMPANY VALUATION 197 11.6 BRAND/PRODUCT COMPARISON 198   11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 198 11.7.1 STARS 198 11.7.2 EMERGING LEADERS 199 11.7.3 PERVASIVE PLAYERS 199 11.7.4 PARTICIPANTS 199 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 200 11.7.5.1 Company footprint 200 11.7.5.2 Region footprint 200 11.7.5.3 Product footprint 201 11.7.5.4 Application footprint 202 11.7.5.5 End-user footprint 203 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024) 203 11.8.1 PROGRESSIVE COMPANIES 203 11.8.2 RESPONSIVE COMPANIES 203 11.8.3 DYNAMIC COMPANIES 204 11.8.4 STARTING BLOCKS 204 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 205 11.8.5.1 Detailed list of key startups/SMEs 205 11.8.5.2 Competitive benchmarking of key startups/SMEs 206 11.9 COMPETITIVE SCENARIO 207 11.9.1 PRODUCT APPROVALS 207 11.9.2 DEALS 208 11.9.3 EXPANSIONS 209 12 COMPANY PROFILES 210 12.1 KEY PLAYERS 210 12.1.1 DANAHER CORPORATION 210 12.1.1.1 Business overview 210 12.1.1.2 Products offered 211 12.1.1.3 Recent developments 214 12.1.1.3.1 Deals 214 12.1.1.3.2 Expansions 215 12.1.1.4 MnM view 215 12.1.1.4.1 Key strengths 215 12.1.1.4.2 Strategic choices 215 12.1.1.4.3 Weaknesses & competitive threats 215 12.1.2 RAYBIOTECH, INC. 216 12.1.2.1 Business overview 216 12.1.2.2 Products offered 216 12.1.2.3 Recent developments 219 12.1.2.3.1 Deals 219   12.1.2.4 MnM view 219 12.1.2.4.1 Key strengths 219 12.1.2.4.2 Strategic choices 219 12.1.2.4.3 Weaknesses & competitive threats 219 12.1.3 MERCK & CO., INC. 220 12.1.3.1 Business overview 220 12.1.3.2 Products offered 221 12.1.3.3 Recent developments 223 12.1.3.3.1 Deals 223 12.1.3.4 MnM view 223 12.1.3.4.1 Key strengths 223 12.1.3.4.2 Strategic choices 224 12.1.3.4.3 Weaknesses & competitive threats 224 12.1.4 AMGEN INC. 225 12.1.4.1 Business overview 225 12.1.4.2 Products offered 226 12.1.4.3 Recent developments 226 12.1.4.3.1 Product approvals 226 12.1.4.3.2 Deals 227 12.1.4.4 MnM view 227 12.1.4.4.1 Key strengths 227 12.1.4.4.2 Strategic choices 227 12.1.4.4.3 Weaknesses & competitive threats 227 12.1.5 ELI LILLY AND COMPANY 228 12.1.5.1 Business overview 228 12.1.5.2 Products offered 229 12.1.5.3 Recent developments 230 12.1.5.3.1 Product approvals 230 12.1.5.3.2 Deals 230 12.1.5.4 MnM view 231 12.1.5.4.1 Key strengths 231 12.1.5.4.2 Strategic choices 231 12.1.5.4.3 Weaknesses & competitive threats 231 12.1.6 F. HOFFMANN-LA ROCHE LTD. 232 12.1.6.1 Business overview 232 12.1.6.2 Products offered 233 12.1.6.3 Recent developments 237 12.1.6.3.1 Product launches & approvals 237 12.1.6.4 Recent developments 238 12.1.6.4.1 Deals 238   12.1.7 NOVO NORDISK A/S 239 12.1.7.1 Business overview 239 12.1.7.2 Products offered 240 12.1.7.3 Recent developments 241 12.1.7.3.1 Deals 241 12.1.8 PFIZER INC. 242 12.1.8.1 Business overview 242 12.1.8.2 Products offered 243 12.1.8.3 Recent developments 244 12.1.8.3.1 Product approvals 244 12.1.8.3.2 Deals 244 12.1.9 THERMO FISHER SCIENTIFIC INC. 245 12.1.9.1 Business overview 245 12.1.9.2 Products offered 246 12.1.10 SANOFI 249 12.1.10.1 Business overview 249 12.1.10.2 Products offered 250 12.1.11 AGILENT TECHNOLOGIES, INC. 251 12.1.11.1 Business overview 251 12.1.11.2 Products offered 252 12.1.11.3 Recent developments 253 12.1.11.3.1 Deals 253 12.1.11.3.2 Expansions 254 12.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED 255 12.1.12.1 Business overview 255 12.1.12.2 Products offered 256 12.1.12.3 Recent developments 256 12.1.12.3.1 Product approvals 256 12.1.13 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF) 257 12.1.13.1 Business overview 257 12.1.13.2 Products offered 258 12.1.13.3 Recent developments 259 12.1.13.3.1 Product launches & approvals 259 12.1.13.3.2 Deals 260 12.1.13.3.3 Expansions 260 12.1.14 BIOCON 261 12.1.14.1 Business overview 261 12.1.14.2 Products offered 262 12.1.14.3 Recent developments 263 12.1.14.3.1 Product approvals 263 12.1.14.3.2 Deals 263   12.2 OTHER PLAYERS 264 12.2.1 AMANO ENZYME INC. 264 12.2.2 ULTREZE ENZYMES 265 12.2.3 NEOGEN 267 12.2.4 BIOLAXI ENZYMES PVT. LTD. 268 12.2.5 GENSCRIPT 270 12.2.6 BIOSEUTICA 271 12.2.7 KERRY GROUP PLC 272 12.2.8 ASSOCIATED BRITISH FOODS PLC 273 12.2.9 K-GENIX GROUP 275 12.2.10 NAGASE & CO., LTD. 276 12.2.11 GRIFOLS, S.A 276 12.2.12 BASF 277 12.2.13 BIO-CAT 278 12.2.14 AMCO PROTEINS 279 12.2.15 PROTALIX BIOTHERAPEUTICS 280 13 RESEARCH METHODOLOGY 281 13.1 RESEARCH DATA 281 13.1.1 SECONDARY RESEARCH 281 13.1.1.1 Key secondary sources 282 13.1.1.2 Objectives of secondary research 282 13.1.1.3 Key data from secondary sources 283 13.1.2 PRIMARY RESEARCH 283 13.1.2.1 Key primary sources 284 13.1.2.2 Key objectives of primary research 284 13.1.2.3 Key industry insights 285 13.2 MARKET SIZE ESTIMATION APPROACH 286 13.2.1 COMPANY REVENUE ESTIMATION APPROACH 287 13.2.2 CUSTOMER-BASED MARKET ESTIMATION 288 13.2.3 TOP-DOWN APPROACH 289 13.3 MARKET FORECASTING APPROACH 291 13.4 DATA TRIANGULATION 292 13.5 MARKET SHARE ASSESSMENT 293 13.6 STUDY ASSUMPTIONS 293 13.7 RESEARCH LIMITATIONS 293 13.8 RISK ANALYSIS 294   14 APPENDIX 295 14.1 DISCUSSION GUIDE 295 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 299 14.3 CUSTOMIZATION OPTIONS 301 14.4 RELATED REPORTS 301 14.5 AUTHOR DETAILS 302
圖表清單 List of Tables & Figures
TABLE 1 PROTEINS & PROTEIN CRYSTALS MARKET: INCLUSIONS & EXCLUSIONS 31 TABLE 2 UNMET NEEDS IN PROTEINS & PROTEIN CRYSTALS MARKET 50 TABLE 3 PROTEINS & PROTEIN CRYSTALS MARKET: PORTER’S FIVE FORCES 51 TABLE 4 AVERAGE SELLING PRICE OF PROTEINS & PROTEIN CRYSTALS, BY KEY PLAYER, 2024 (USD) 57 TABLE 5 AVERAGE SELLING PRICE TREND OF PROTEINS & PROTEIN CRYSTALS, BY REGION, 2022–2024 (USD) 59 TABLE 6 IMPORT DATA FOR HS CODE 3507, BY COUNTRY, 2021–2024 (USD THOUSAND) 61 TABLE 7 EXPORT DATA FOR HS CODE 3507, BY COUNTRY, 2021–2024 (USD THOUSAND) 62 TABLE 8 IMPORT DATA FOR HS CODE 293719, BY COUNTRY, 2021─2024 (USD THOUSAND) 63 TABLE 9 EXPORT DATA FOR HS CODE 293719, BY COUNTRY, 2021─2024 (USD THOUSAND) 64 TABLE 10 LIST OF MAJOR CONFERENCES & EVENTS IN PROTEINS & PROTEIN CRYSTALS MARKET, JANUARY 2025–DECEMBER 2026 65 TABLE 11 CASE STUDY: COMPUTATIONAL DESIGN OF HIGH-AFFINITY MINIBINDER PROTEINS FOR THERAPEUTIC TARGETS 68 TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 69 TABLE 13 CASE STUDY: ALPHAFOLD BY DEEPMIND 73 TABLE 14 KEY REGULATORY AGENCIES 76 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 19 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 20 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 21 INDUSTRY STANDARDS FOR PROTEINS & PROTEIN CRYSTALS MARKET 81 TABLE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS IN PROTEINS & PROTEIN CRYSTALS MARKET (%) 83 TABLE 23 KEY BUYING CRITERIA FOR MAJOR END USERS IN PROTEINS & PROTEIN CRYSTALS MARKET 84 TABLE 24 PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 87 TABLE 25 ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 88 TABLE 26 ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 88 TABLE 27 ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET FOR INDUSTRIAL ENZYMES, BY REGION, 2023–2030 (USD BILLION) 89 TABLE 28 ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET FOR FOOD ENZYMES, BY REGION, 2023–2030 (USD BILLION) 90 TABLE 29 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 91 TABLE 30 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 91 TABLE 31 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION) 92 TABLE 32 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET FOR INSULIN, BY REGION, 2023–2030 (USD BILLION) 93 TABLE 33 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET FOR HORMONES, BY REGION, 2023–2030 (USD BILLION) 94 TABLE 34 THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET FOR COAGULATION FACTORS, BY REGION, 2023–2030 (USD BILLION) 95 TABLE 35 STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 96 TABLE 36 STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 96 TABLE 37 STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET FOR RESEARCH PROTEINS, BY REGION, 2023–2030 (USD BILLION) 97 TABLE 38 STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2023–2030 (USD BILLION) 98 TABLE 39 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 99 TABLE 40 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 99 TABLE 41 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET FOR INDUSTRIAL PROTEINS, BY REGION, 2023–2030 (USD BILLION) 100 TABLE 42 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET FOR NUTRITIONAL PROTEINS, BY REGION, 2023–2030 (USD BILLION) 101 TABLE 43 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET FOR ANALYTICAL PROTEINS, BY REGION, 2023–2030 (USD BILLION) 102 TABLE 44 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET FOR COSMECEUTICAL PROTEINS, BY REGION, 2023–2030 (USD BILLION) 103 TABLE 45 SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET FOR FUNCTIONAL FOOD PROTEINS, BY REGION, 2023–2030 (USD BILLION) 104 TABLE 46 PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 106 TABLE 47 PROTEINS & PROTEIN CRYSTALS APPLICATIONS MARKET, BY REGION, 2023–2030 (USD BILLION) 106 TABLE 48 PROTEINS & PROTEIN CRYSTALS MARKET FOR HEALTHCARE, BY REGION, 2023–2030 (USD BILLION) 107 TABLE 49 PROTEINS & PROTEIN CRYSTALS MARKET FOR TISSUE ENGINEERING, BY REGION, 2023–2030 (USD BILLION) 108 TABLE 50 PROTEINS & PROTEIN CRYSTALS MARKET FOR AGRICULTURE & ANIMAL NUTRITION, BY REGION, 2023–2030 (USD BILLION) 109 TABLE 51 PROTEINS & PROTEIN CRYSTALS MARKET FOR INDUSTRIAL PROCESSING, BY REGION, 2023–2030 (USD BILLION) 110 TABLE 52 PROTEINS & PROTEIN CRYSTALS MARKET FOR BIOENERGY & ENVIRONMENTAL, BY REGION, 2023–2030 (USD BILLION) 111 TABLE 53 PROTEINS & PROTEIN CRYSTALS MARKET FOR COSMECEUTICAL & NUTRACEUTICALS, BY REGION, 2023–2030 (USD BILLION) 112 TABLE 54 PROTEINS & PROTEIN CRYSTALS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD BILLION) 113 TABLE 55 PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 115 TABLE 56 PROTEINS & PROTEIN CRYSTALS MARKET FOR PHARMA INDUSTRY, BY TYPE, 2023–2030 (USD BILLION) 116 TABLE 57 PROTEINS & PROTEIN CRYSTALS MARKET FOR PHARMA INDUSTRY, BY REGION, 2023–2030 (USD BILLION) 116 TABLE 58 PHARMA INDUSTRY MARKET FOR DRUG DEVELOPMENT, BY REGION, 2023–2030 (USD BILLION) 117 TABLE 59 PHARMA INDUSTRY MARKET FOR FORMULATION/MANUFACTURING, BY REGION, 2023–2030 (USD BILLION) 118 TABLE 60 PHARMA INDUSTRY MARKET FOR STORAGE/INVENTORY MANAGEMENT, BY REGION, 2023–2030 (USD BILLION) 119 TABLE 61 PROTEINS & PROTEIN CRYSTALS MARKET FOR BIOTECHNOLOGY INDUSTRY, BY TYPE, 2023–2030 (USD BILLION) 119 TABLE 62 PROTEINS & PROTEIN CRYSTALS MARKET FOR BIOTECHNOLOGY INDUSTRY, BY REGION, 2023–2030 (USD BILLION) 120 TABLE 63 BIOTECHNOLOGY INDUSTRY MARKET FOR DRUG DEVELOPMENT, BY REGION, 2023–2030 (USD BILLION) 121 TABLE 64 BIOTECHNOLOGY INDUSTRY MARKET FOR FORMULATION/MANUFACTURING, BY REGION, 2023–2030 (USD BILLION) 122 TABLE 65 BIOTECHNOLOGY INDUSTRY MARKET FOR STORAGE/INVENTORY MANAGEMNET, BY REGION, 2023–2030 (USD BILLION) 123 TABLE 66 PROTEINS & PROTEIN CRYSTALS MARKET FOR RESEARCH, ACADEMIA, AND CROS, BY TYPE, 2023–2030 (USD BILLION) 124 TABLE 67 PROTEINS & PROTEIN CRYSTALS MARKET FOR RESEARCH, ACADEMIA, AND CROS, BY REGION, 2023–2030 (USD BILLION) 124 TABLE 68 RESEARCH, ACADEMIA, AND CROS MARKET FOR DRUG DEVELOPMENT & DISCOVERY, BY REGION, 2023–2030 (USD BILLION) 125 TABLE 69 RESEARCH, ACADEMIA, AND CROS MARKET FOR LIFE SCIENCE RESEARCH, BY REGION, 2023–2030 (USD BILLION) 126 TABLE 70 PROTEINS & PROTEIN CRYSTALS MARKET FOR FOOD & BEVERAGE INDUSTRY, BY REGION, 2023–2030 (USD BILLION) 126 TABLE 71 PROTEINS & PROTEIN CRYSTALS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION) 127 TABLE 72 PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 129 TABLE 73 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 130 TABLE 74 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 131 TABLE 75 NORTH AMERICA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 131 TABLE 76 NORTH AMERICA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 131 TABLE 77 NORTH AMERICA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 132 TABLE 78 NORTH AMERICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 132 TABLE 79 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 133 TABLE 80 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 133 TABLE 81 US: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 134 TABLE 82 US: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 135 TABLE 83 US: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 135 TABLE 84 US: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 135 TABLE 85 US: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 136 TABLE 86 CANADA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 137 TABLE 87 CANADA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 137 TABLE 88 CANADA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 137 TABLE 89 CANADA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 138 TABLE 90 CANADA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 138 TABLE 91 EUROPE: PROTEINS & PROTEIN CRYSTALS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 139 TABLE 92 EUROPE: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 139 TABLE 93 EUROPE: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE 2023–2030 (USD BILLION) 139 TABLE 94 EUROPE: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 140 TABLE 95 EUROPE: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE 2023–2030 (USD BILLION) 140 TABLE 96 EUROPE: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 140 TABLE 97 EUROPE: PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 141 TABLE 98 EUROPE: PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 141 TABLE 99 GERMANY: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 142 TABLE 100 GERMANY: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 142 TABLE 101 GERMANY: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 143 TABLE 102 GERMANY: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 143 TABLE 103 GERMANY: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 143 TABLE 104 UK: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 144 TABLE 105 UK: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 145 TABLE 106 UK: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 145 TABLE 107 UK: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 145 TABLE 108 UK: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 146 TABLE 109 FRANCE: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 147 TABLE 110 FRANCE: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 147 TABLE 111 FRANCE: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 148 TABLE 112 FRANCE: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 148 TABLE 113 FRANCE: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 148 TABLE 114 ITALY: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 149 TABLE 115 ITALY: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 150 TABLE 116 ITALY: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 150 TABLE 117 ITALY: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 150 TABLE 118 ITALY: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 151 TABLE 119 SPAIN: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 152 TABLE 120 SPAIN: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 152 TABLE 121 SPAIN: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 152 TABLE 122 SPAIN: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 153 TABLE 123 SPAIN: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 153 TABLE 124 REST OF EUROPE: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 154 TABLE 125 REST OF EUROPE: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 154 TABLE 126 REST OF EUROPE: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 154 TABLE 127 REST OF EUROPE: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 155 TABLE 128 REST OF EUROPE: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 155 TABLE 129 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 156 TABLE 130 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 157 TABLE 131 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 157 TABLE 132 ASIA PACIFIC: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 157 TABLE 133 ASIA PACIFIC: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 158 TABLE 134 ASIA PACIFIC: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 158 TABLE 135 ASIA PACIFIC: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 158 TABLE 136 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 159 TABLE 137 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 159 TABLE 138 CHINA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 160 TABLE 139 CHINA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 160 TABLE 140 CHINA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 160 TABLE 141 CHINA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 161 TABLE 142 CHINA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 161 TABLE 143 JAPAN: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 162 TABLE 144 JAPAN: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 163 TABLE 145 JAPAN: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 163 TABLE 146 JAPAN: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 163 TABLE 147 JAPAN: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 164 TABLE 148 INDIA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 165 TABLE 149 INDIA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 165 TABLE 150 INDIA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 166 TABLE 151 INDIA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 166 TABLE 152 INDIA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 166 TABLE 153 AUSTRALIA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 167 TABLE 154 AUSTRALIA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 168 TABLE 155 AUSTRALIA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 168 TABLE 156 AUSTRALIA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 168 TABLE 157 AUSTRALIA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 169 TABLE 158 SOUTH KOREA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 170 TABLE 159 SOUTH KOREA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 170 TABLE 160 SOUTH KOREA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 170 TABLE 161 SOUTH KOREA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 171 TABLE 162 SOUTH KOREA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 171 TABLE 163 REST OF ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 172 TABLE 164 REST OF ASIA PACIFIC: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 172 TABLE 165 REST OF ASIA PACIFIC: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 172 TABLE 166 REST OF ASIA PACIFIC: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 173 TABLE 167 REST OF ASIA PACIFIC: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 168 LATIN AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 174 TABLE 169 LATIN AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 174 TABLE 170 LATIN AMERICA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 175 TABLE 171 LATIN AMERICA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 175 TABLE 172 LATIN AMERICA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 175 TABLE 173 LATIN AMERICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 176 TABLE 174 LATIN AMERICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 176 TABLE 175 LATIN AMERICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 177 TABLE 176 BRAZIL: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 178 TABLE 177 BRAZIL: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 178 TABLE 178 BRAZIL: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 178 TABLE 179 BRAZIL: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 179 TABLE 180 BRAZIL: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 179 TABLE 181 MEXICO: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 180 TABLE 182 MEXICO: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 180 TABLE 183 MEXICO: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 181 TABLE 184 MEXICO: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 181 TABLE 185 MEXICO: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 181 TABLE 186 REST OF LATIN AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 182 TABLE 187 REST OF LATIN AMERICA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 182 TABLE 188 REST OF LATIN AMERICA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 183 TABLE 189 REST OF LATIN AMERICA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 183 TABLE 190 REST OF LATIN AMERICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 183 TABLE 191 MIDDLE EAST & AFRICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY REGION, 2023–2030 (USD BILLION) 184 TABLE 192 MIDDLE EAST & AFRICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 185 TABLE 193 MIDDLE EAST & AFRICA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 185 TABLE 194 MIDDLE EAST & AFRICA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 185 TABLE 195 MIDDLE EAST & AFRICA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 186 TABLE 196 MIDDLE EAST & AFRICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 186 TABLE 197 MIDDLE EAST & AFRICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 187 TABLE 198 MIDDLE EAST & AFRICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY END USER, 2023–2030 (USD BILLION) 187 TABLE 199 GCC COUNTRIES: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 188 TABLE 200 GCC COUNTRIES: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 188 TABLE 201 GCC COUNTRIES: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 189 TABLE 202 GCC COUNTRIES: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 189 TABLE 203 GCC COUNTRIES: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 189 TABLE 204 REST OF MIDDLE EAST & AFRICA: PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 190 TABLE 205 REST OF MIDDLE EAST & AFRICA: ENZYMATIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 190 TABLE 206 REST OF MIDDLE EAST & AFRICA: THERAPEUTIC PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 191 TABLE 207 REST OF MIDDLE EAST & AFRICA: STRUCTURAL PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 191 TABLE 208 REST OF MIDDLE EAST & AFRICA: SPECIALTY PROTEINS & PROTEIN CRYSTALS MARKET, BY TYPE, 2023–2030 (USD BILLION) 191 TABLE 209 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN PROTEINS & PROTEIN CRYSTALS MARKET 192 TABLE 210 PROTEINS & PROTEIN CRYSTALS MARKET: DEGREE OF COMPETITION 195 TABLE 211 PROTEINS & PROTEIN CRYSTALS MARKET: REGION FOOTPRINT 200 TABLE 212 PROTEINS & PROTEIN CRYSTALS MARKET: PRODUCT FOOTPRINT 201 TABLE 213 PROTEINS & PROTEIN CRYSTALS MARKET: APPLICATION FOOTPRINT 202 TABLE 214 PROTEINS & PROTEIN CRYSTALS MARKET: END-USER FOOTPRINT 203 TABLE 215 PROTEINS & PROTEIN CRYSTALS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 205 TABLE 216 PROTEINS & PROTEIN CRYSTALS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY REGION 206 TABLE 217 PROTEINS & PROTEIN CRYSTALS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT TYPE 206 TABLE 218 PROTEINS & PROTEIN CRYSTALS MARKET: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 207 TABLE 219 PROTEINS & PROTEIN CRYSTALS MARKET: DEALS, JANUARY 2022–DECEMBER 2025 208 TABLE 220 PROTEINS & PROTEIN CRYSTALS MARKET: DEALS, JANUARY 2022–DECEMBER 2025 209 TABLE 221 DANAHER CORPORATION: COMPANY OVERVIEW 210 TABLE 222 DANAHER CORPORATION: PRODUCTS OFFERED 211 TABLE 223 DANAHER CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 214 TABLE 224 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–DECEMBER 2025 215 TABLE 225 RAYBIOTECH, INC.: COMPANY OVERVIEW 216 TABLE 226 RAYBIOTECH, INC.: PRODUCTS OFFERED 216 TABLE 227 RAYBIOTECH, INC.: DEALS, JANUARY 2022–DECEMBER 2025 219 TABLE 228 MERCK & CO., INC.: COMPANY OVERVIEW 220 TABLE 229 MERCK & CO., INC.: PRODUCTS OFFERED 221 TABLE 230 MERCK & CO., INC.: DEALS, JANUARY 2022–DECEMBER 2025 223 TABLE 231 AMGEN INC.: COMPANY OVERVIEW 225 TABLE 232 AMGEN INC.: PRODUCTS OFFERED 226 TABLE 233 AMGEN INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 226 TABLE 234 AMGEN INC.: DEALS, JANUARY 2022–DECEMBER 2025 227 TABLE 235 ELI LILLY AND COMPANY: COMPANY OVERVIEW 228 TABLE 236 ELI LILLY AND COMPANY: PRODUCTS OFFERED 229 TABLE 237 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 230 TABLE 238 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–DECEMBER 2025 230 TABLE 239 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 232 TABLE 240 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 233 TABLE 241 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–DECEMBER 2025 237 TABLE 242 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–DECEMBER 2025 238 TABLE 243 NOVO NORDISK A/S: COMPANY OVERVIEW 239 TABLE 244 NOVO NORDISK A/S: PRODUCTS OFFERED 240 TABLE 245 NOVO NORDISK A/S: DEALS, JANUARY 2022–DECEMBER 2025 241 TABLE 246 PFIZER INC.: COMPANY OVERVIEW 242 TABLE 247 PFIZER INC.: PRODUCTS OFFERED 243 TABLE 248 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 244 TABLE 249 PFIZER INC.: DEALS, JANUARY 2022–DECEMBER 2025 244 TABLE 250 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 245 TABLE 251 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 246 TABLE 252 SANOFI: COMPANY OVERVIEW 249 TABLE 253 SANOFI: PRODUCTS OFFERED 250 TABLE 254 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 251 TABLE 255 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 252 TABLE 256 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–DECEMBER 2025 253 TABLE 257 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–DECEMBER 2025 254 TABLE 258 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 255 TABLE 259 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED 256 TABLE 260 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 256 TABLE 261 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): COMPANY OVERVIEW 257 TABLE 262 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): PRODUCTS OFFERED 258 TABLE 263 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–DECEMBER 2025 259 TABLE 264 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): DEALS, JANUARY 2022–DECEMBER 2025 260 TABLE 265 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): EXPANSIONS, JANUARY 2022–DECEMBER 2025 260 TABLE 266 BIOCON: COMPANY OVERVIEW 261 TABLE 267 BIOCON: PRODUCTS OFFERED 262 TABLE 268 BIOCON: PRODUCT APPROVALS, JANUARY 2022–DECEMBER 2025 263 TABLE 269 BIOCON: DEALS, JANUARY 2022–DECEMBER 2025 263 TABLE 270 AMANO ENZYME INC.: COMPANY OVERVIEW 264 TABLE 271 ULTREZE ENZYMES: COMPANY OVERVIEW 265 TABLE 272 NEOGEN: COMPANY OVERVIEW 267 TABLE 273 BIOLAXI ENZYMES PVT. LTD.: COMPANY OVERVIEW 268 TABLE 274 GENSCRIPT: COMPANY OVERVIEW 270 TABLE 275 BIOSEUTICA: COMPANY OVERVIEW 271 TABLE 276 KERRY GROUP PLC: COMPANY OVERVIEW 272 TABLE 277 ASSOCIATED BRITISH FOODS PLC: COMPANY OVERVIEW 273 TABLE 278 K-GENIX GROUP: COMPANY OVERVIEW 275 TABLE 279 NAGASE & CO., LTD.: COMPANY OVERVIEW 276 TABLE 280 GRIFOLS, S.A : COMPANY OVERVIEW 276 TABLE 281 BASF: COMPANY OVERVIEW 277 TABLE 282 BIO-CAT: COMPANY OVERVIEW 278 TABLE 283 AMCO PROTEINS: COMPANY OVERVIEW 279 TABLE 284 PROTALIX BIOTHERAPEUTICS: COMPANY OVERVIEW 280 TABLE 285 PROTEINS & PROTEIN CRYSTALS MARKET: STUDY ASSUMPTIONS 293 TABLE 286 PROTEINS & PROTEIN CRYSTALS MARKET: RISK ANALYSIS 294 FIGURE 1 PROTEINS & PROTEIN CRYSTALS MARKET SEGMENTATION & REGIONAL SCOPE 30 FIGURE 2 PROTEINS & PROTEIN CRYSTALS MARKET: YEARS CONSIDERED 31 FIGURE 3 MARKET SCENARIO FOR PROTEINS & PROTEIN CRYSTALS MARKET 33 FIGURE 4 GLOBAL PROTEINS & PROTEIN CRYSTALS MARKET, BY PRODUCT, 2024–2030 (USD BILLION) 33 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET, 2021–2024 34 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PROTEINS & PROTEIN CRYSTALS MARKET 35 FIGURE 7 HIGH-GROWTH SEGMENTS IN PROTEINS & PROTEIN CRYSTALS MARKET, 2025–2030 36 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 37 FIGURE 9 RAPID EXPANSION OF BIOLOGICS AND RECOMBINANT PROTEIN THERAPEUTICS TO PROPEL MARKET GROWTH 38 FIGURE 10 GLOBAL FORMULATIONS/END PRODUCTS, PROTEINS & PROTEIN CRYSTALS & CRYSTAALLOGRAPHY MARKET, BY PRODUCT SEGMENT, 2025-2030 (USD BILLION) 39 FIGURE 11 US AND PHARMA INDUSTRY COMMANDED LARGEST MARKET SHARE IN 2025 40 FIGURE 12 CHINA TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 41 FIGURE 13 PROTEINS & PROTEIN CRYSTALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 14 PROTEINS & PROTEIN CRYSTALS MARKET: PORTER’S FIVE FORCES ANALYSIS 51 FIGURE 15 PROTEINS & PROTEIN CRYSTALS MARKET: SUPPLY CHAIN ANALYSIS 55 FIGURE 16 PROTEINS & PROTEIN CRYSTALS MARKET: VALUE CHAIN ANALYSIS 56 FIGURE 17 PROTEINS & PROTEIN CRYSTALS MARKET: ECOSYSTEM ANALYSIS 57 FIGURE 18 AVERAGE SELLING PRICE OF PROTEINS & PROTEIN CRYSTALS, BY PRODUCT, 2024 (USD) 58 FIGURE 19 AVERAGE SELLING PRICE OF PROTEINS & PROTEIN CRYSTALS, BY REGION, 2024 (USD THOUSAND) 59 FIGURE 20 PROTEINS & PROTEIN CRYSTALS MARKET: IMPORT DATA FOR HS CODE 3507, 2021–2024 61 FIGURE 21 PROTEINS & PROTEIN CRYSTALS MARKET: EXPORT DATA FOR HS CODE 3507, 2021–2024 62 FIGURE 22 PROTEINS & PROTEIN CRYSTALS MARKET: IMPORT SCENARIO FOR HS CODE 293719, 2021–2024 63 FIGURE 23 PROTEINS & PROTEIN CRYSTALS MARKET: EXPORT SCENARIO FOR HS CODE 293719, BY COUNTRY, 2021–2024 (USD THOUSAND) 64 FIGURE 24 PROTEINS & PROTEIN CRYSTALS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 66 FIGURE 25 FUNDING AND NUMBER OF DEALS IN PROTEINS & PROTEIN CRYSTALS MARKET, 2019–2023 (USD MILLION) 67 FIGURE 26 NUMBER OF INVESTOR DEALS IN PROTEINS & PROTEIN CRYSTALS MARKET, BY KEY PLAYER, 2019–2023 67 FIGURE 27 VALUE OF INVESTOR DEALS IN PROTEINS & PROTEIN CRYSTALS MARKET, BY KEY PLAYER, 2019–2023 (USD MILLION) 68 FIGURE 28 PATENT ANALYSIS FOR PROTEINS & PROTEIN CRYSTALS MARKET (JANUARY 2014–NOVEMBER 2025) 72 FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS IN PROTEINS & PROTEIN CRYSTALS MARKET 83 FIGURE 30 KEY BUYING CRITERIA FOR MAJOR END USERS IN PROTEINS & PROTEIN CRYSTALS MARKET 84 FIGURE 31 NORTH AMERICA: PROTEINS & PROTEIN CRYSTALS MARKET SNAPSHOT 130 FIGURE 32 ASIA PACIFIC: PROTEINS & PROTEIN CRYSTALS MARKET SNAPSHOT 156 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET, 2021–2024 (USD MILLION) 194 FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET (2024) 195 FIGURE 35 RANKING OF KEY PLAYERS IN PROTEINS & PROTEIN CRYSTALS MARKET (2024) 196 FIGURE 36 EV/EBITDA OF KEY VENDORS 197 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 197 FIGURE 38 PROTEINS & PROTEIN CRYSTALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 198 FIGURE 39 PROTEINS & PROTEIN CRYSTALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 199 FIGURE 40 PROTEINS & PROTEIN CRYSTALS MARKET: COMPANY FOOTPRINT 200 FIGURE 41 PROTEINS & PROTEIN CRYSTALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 204 FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT 211 FIGURE 43 MERCK & CO., INC.: COMPANY SNAPSHOT 221 FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT 225 FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 228 FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 232 FIGURE 47 NOVO NORDISK A/S: COMPANY SNAPSHOT 240 FIGURE 48 PFIZER INC.: COMPANY SNAPSHOT 243 FIGURE 49 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 245 FIGURE 50 SANOFI: COMPANY SNAPSHOT 249 FIGURE 51 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 252 FIGURE 52 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT 255 FIGURE 53 INTERNATIONAL FLAVOURS & FRAGRANCES INC. (IFF): COMPANY SNAPSHOT 258 FIGURE 54 BIOCON: COMPANY SNAPSHOT 262 FIGURE 55 PROTEINS & PROTEIN CRYSTALS MARKET: RESEARCH DESIGN 281 FIGURE 56 PROTEINS & PROTEIN CRYSTALS MARKET: KEY SECONDARY SOURCES 282 FIGURE 57 PROTEINS & PROTEIN CRYSTALS MARKET: KEY DATA FROM SECONDARY SOURCES 283 FIGURE 58 PROTEINS & PROTEIN CRYSTALS MARKET: PRIMARY SOURCES (SUPPLY AND DEMAND SIDES) 284 FIGURE 59 PROTEINS & PROTEIN CRYSTALS MARKET: KEY INDUSTRY INSIGHTS 285 FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 285 FIGURE 61 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 286 FIGURE 62 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 287 FIGURE 63 PROTEINS & PROTEIN CRYSTALS MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 288 FIGURE 64 PROTEINS & PROTEIN CRYSTALS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 289 FIGURE 65 PROTEINS & PROTEIN CRYSTALS MARKET: TOP-DOWN APPROACH 289 FIGURE 66 GLOBAL PROTEINS & PROTEIN CRYSTALS MARKET GROWTH PROJECTIONS 291 FIGURE 67 PROTEINS & PROTEIN CRYSTALS MARKET: DATA TRIANGULATION METHODOLOGY 292

同分類最新報告（機械與設備）

查看機械與設備全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們